NutriStack
What is happening. Bempedoic acid lowers LDL cholesterol via inhibition of ATP-citrate lyase, while prescription-grade omega-3 fatty acids (especially icosapent ethyl) primarily lower triglycerides and, in high-risk patients, reduce cardiovascular events. The two are commonly used together as part of a comprehensive lipid-lowering strategy, often alongside or as an alternative to statins. There is no pharmacokinetic conflict, and the lipid-lowering and triglyceride-lowering effects are complementary rather than overlapping.
Mechanism. Distinct, non-overlapping mechanisms: bempedoic acid inhibits hepatic ATP-citrate lyase upstream of HMG-CoA reductase to reduce cholesterol synthesis and upregulate LDL receptors, whereas omega-3 fatty acids reduce hepatic VLDL-triglyceride production and enhance triglyceride clearance. No shared metabolic pathway or competition for elimination.
Recommendation. Combining fish oil (or prescription omega-3s) with bempedoic acid is reasonable for patients who need both LDL and triglyceride control. Use this combination as directed by the prescriber and continue to monitor a full lipid panel. High-dose fish oil can modestly increase bleeding tendency and, with icosapent ethyl, atrial fibrillation risk, so disclose all supplements to your clinician.